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The majority of the epigenomic reports in hepatocellular carcinoma have focused on identifying novel differentially methylated
drivers or passengers of the oncogenic process. Few reports have considered the technologies in place for clinical translation of
newly identified biomarkers. The aim of this study was to identify epigenomic technologies that need only a small number of
samples to discriminate HCC from non-HCC tissue, a basic requirement for biomarker development trials. To assess that potential,
we used quantitative Methylation Specific PCR, oligonucleotide tiling arrays, andMethylation BeadChip assays. Concurrent global
DNA hypomethylation, gene-specific hypermethylation, and chromatin alterations were observed as a hallmark of HCC. A global
loss of promoter methylation was observed in HCC with the Illumina BeadChip assays and the Nimblegen oligonucleotide arrays.
HCC samples had lower median methylation peak scores and a reduced number of significant promoter-wide methylated probes.
Promoter hypermethylation of RASSF1A, SSBP2, and B4GALT1 quantified by qMSP had a sensitivity ranging from 38% to 52%, a
specificity of 100%, and an AUC from 0.58 to 0.75. A panel combining these genes with HCC risk factors had a sensitivity of 87%,
a specificity of 100%, and an AUC of 0.91.
1. Introduction
Promoter-wide alterations of DNA methylation have been
described at all stages that encompass hepatocarcinogenesis,
precancerous lesions, and tumor initiation to unresectable
HCC [1, 2], mostly focusing on aberrant hypermethylation of
CpG islands in gene promoter regions near the Transcription
Start Site (TSS) [3, 4]. Several hypermethylated genes have
been identified using a range of diverse technologies. On
the other hand, studies are also reporting promoter hypo-
methylation in specific genes to play an important role in
HCC [5, 6], suggesting that high frequencies of hypomethy-
lation, in various cancers, would be valuable as a cancer
diagnostic marker.
The earlier methylation studies of HCC used the can-
didate gene approach and first generation methylation
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microarrays, which study less than 7K CpG islands [7].
A recent number of studies have used Methylated DNA
immunoprecipitation-on-chip analysis (MeDIP-chip) [8] and
BeadChip assay technologies to identify novel genes differen-
tially methylated in HCC [9]. Most HCCmethylation studies
have used available technologies to profile and identify dif-
ferentially methylated genes that drive the oncogenic process
[10].
The contribution ofDNAmethylation to the development
of HCC is not yet elucidated. A methylation study in HCC is
also challenging as there are several well-known risk factors
for HCC, such as alcohol-induced cirrhosis and chronic viral
hepatitis B or C infection [11]. Aberrant DNA methylation
profiles across the genome were identified in tumor tissues
from US HCC cases that are predominantly related to HCV
infection [12]. Yet not much emphasis has been placed on
using existing methylation platforms to evaluate differen-
tially methylated genes as biomarkers of HCC, regardless of
whether these alterations are driving the oncogenic process
or are molecular changes that occur during malignant trans-
formation.
We selected two existing methylation platforms to sepa-
rately distinguish between HCC and non-HCC liver tissue in
a small number of samples: an oligonucleotide methylation
tiling array (MeDIP-chip, Nimblegen’s 385K Promoter, and
CpG Island methylation array) and the Infinium Human
Methylation 27K BeadChip assay (Illumina). We then gen-
erated a list of hypermethylated genes based on both the
frequency in which the genes had been identified as methy-
lated in different studies and also in the methylation arrays
we used. From this list, we chose three genes for validation
in an independent cohort comprised of HCC and adjacent
nonpathological samples using quantitative Methylation-
Specific PCR (qMSP). The focus of the study was to identify
whether methylation platforms stratifying a small sample
size together with publicly available genomic and epigenomic
databases could be deployed in biomarker development trials.
The methylation platforms can be used as stand-alone tools
or as complementary platforms to other transomic tools,
depending on the scientific question.
2. Materials and Methods
2.1. Patient Selection. Deidentified frozen primary HCC,
adjacent nontumor (cirrhotic and noncirrhotic), and normal
liver (noncirrhotic tissue obtained from autopsies) tissue
samples were obtained from the Johns Hopkins University
School of Medicine and the Human Cooperative Tissue Net-
work. The study protocol conforms to the ethical guidelines
of the 1975 Declaration of Helsinki as reflected in a priori
approval by the Johns Hopkins Institutional Review Board.
All patients had not undergone therapy prior to sample
collection. The samples were frozen in liquid nitrogen and
stored at −80∘C.
2.2. DNA Extraction, Bisulfite Conversion, andMeDIP Enrich-
ment. Tissue samples were digested with 1% SDS and
50𝜇g/mL proteinase K (Bushranger Mannheim) at 48∘C
overnight, followed by phenol/chloroform extraction and
ethanol precipitation of DNA as previously described [13].
Prior to using qMSP and the Illumina BeadChip assay, bisul-
fite modification of 2 𝜇g of genomic DNA was performed as
previously described [14]. Prior to using the Nimblegen tiling
arrays, 500 ng of genomic DNA was sheared using a water
bath sonicator (Bioruptor UCD-200, Diagenode). Sonicated
DNAwas then analyzed on a 1.5% agarose gel to ensure that it
had an optimal size of 200–1000 bp.MeDIPwas subsequently
performed with the Methyl DNA Immunoprecipitation Kit
(Epigentek). Fractions of Input DNA and Immunoprecip-
itated DNA from each sample were subsequently sent to
Nimblegen for labeling, hybridization, and scanning.
2.3. Illumina BeadChip Array. Bisulfite-treated DNA from
3HCC samples and 3 adjacent normal liver samples was
hybridized to the Human Methylation 27K BeadChip, which
quantitatively interrogates 27,578 CpG loci covering more
than 14,000 genes at single-nucleotide resolution. The Infin-
ium Methylation assay detects cytosine methylation at CpG
islands based on highly multiplexed genotyping of bisulfite-
converted genomic DNA (gDNA). The assay interrogates
these chemically differentiated loci using two site-specific
probes, one designed for the methylated locus (M bead
type) and another for the unmethylated locus (U bead type).
Single-base extension of the probes incorporates a labeled
ddNTP, which is subsequently stained with a fluorescence
reagent. The level of methylation for the interrogated locus
can be determined by calculating the ratio of the fluorescent
signals from the methylated versus unmethylated sites.
2.4. Nimblegen 385K CpG Island Plus Promoter Array. DNA
(500 ng) from 3 liver tissue samples (1HCC and 2 non-
cirrhotic normal liver samples) enriched with MeDIP were
hybridized to Nimblegen Promoter plus CpG Island 385K
oligonucleotide tiling arrays. A single array design covers
28,226 CpG islands and promoter regions for 17,000 RefSeq
genes. The promoter region covered is 1 kb long: 800 bp
upstream from the TSS and 200 bp downstream from the
TSS. Small CpG islands are extended at both ends for a total
additional coverage of 700 bp for more reliable detection.
DNAmethylation positive control regions, such as the HoxA
gene cluster, H19/IGF2 cluster, KCNQ1 cluster, and IGF2R
gene, are also included on the array.
2.5. Spotfire Analysis and Heat map Creation. The beta values
of all probes on the Illumina Infinium arrays were subjected
to log10 transformation in order to generate a dendrogram
and corresponding heat map based on unsupervised hierar-
chical clustering with Spotfire (Somerville, MA). The clus-
tering was performed with the unweighted average method
using correlation as the similarity measure and ordering by
average values.
2.6. Bioinformatics Analysis of Methylation Array Data. The
Microarray Core at Johns Hopkins School of Medicine per-
formed the bioinformatics analysis of the Infinium array data
using Illumina’s proprietary BeadStudio software package
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to provide average methylation Beta values for each probe.
Nimblegen performed the bioinformatics analysis for the
385K CpG Island Plus Promoter Array. Nimblegen uses the
ACMEalgorithm to identify hypermethylated genes that have
a statistically significant methylation peak score above 2 [15].
2.7. Gene Selection from Public Databases of Known Methy-
lation Events in Cancer. Candidate gene selection for pro-
moter methylation analysis was performed utilizing existing
databases of known methylation events in cancer [16, 17]. We
generated a list of hypermethylated genes based on both the
frequency in which the genes had been identified as methy-
lated in different studies and also in the methylation arrays
we used. From this list, we chose three genes for validation
in an independent cohort comprised of HCC and adjacent
nonpathological samples using quantitative Methylation-
Specific PCR (qMSP). qMSP primers and probes span an
800 bp region upstream from the TSS. The genes cho-
sen were sequence-specific single-stranded DNA-binding
protein 2 (SSBP2), which has been previously shown to
be hypermethylated in other solid tumors [18], beta-1,4-
galactosyltransferase-1 (B4GALT1), not previously shown
to be hypermethylated in cancer, and the Ras association
domain family member 1 (RASSF1A), already shown to be
hypermethylated in HCC [10].
2.8. Quantitative Methylation-Specific PCR. DNA from 27
HCC and 22 adjacent normal tissue samples (cirrhotic,
noncirrhotic, and cryptogenic) was bisulfite treated and
analyzed with qMSP. Fluorogenic PCR reactions were carried
out in a reaction volume of 20 𝜇L consisting of 600 nmol/L
of each primer, 200𝜇mol/L probe, 0.75 units platinum Taq
polymerase (Invitrogen), 200𝜇mol/L of each dATP, dCTP,
dGTP, and dTTP, 200 nmol/L ROX dye reference (Invitro-
gen), 16.6mmol/L ammonium sulfate, 67mmol/L Trizma
(Sigma, St. Louis, MO), 6.7mmol/L magnesium chloride,
10mmol/L mercaptoethanol, and 0.1% DMSO. Duplicates
of three microliters (3 𝜇L) of bisulfite-modified DNA solu-
tion were used in each real-time methylation-specific PCR
(qMSP) amplification reaction. Primers and probes were
designed to specifically amplify the promoters of the three
genes of interest (RASSF1A, SSBP2, and B4GALT1) and the
promoter of a reference gene, actin-B (ACTB). Primer and
probe sequences and annealing temperatures are provided in
Supplementary Table 1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2014/597164.
Amplification reactions were carried out in 384-well
plates in a 7900HT Fast Real-Time PCR System (Applied
Biosystems) and were analyzed by SDS 2.2.1 Sequence
Detector System (Applied Biosystems). Thermal cycling was
initiated with a first denaturation step at 95∘C for 3 minutes,
followed by 40 cycles of 95∘C for 15 seconds, and 58∘C
for 1 minute. Each plate included patient DNA samples,
positive (Bisulfite-converted Universal Methylated Human
DNAStandard, ZymoResearch) and negative (normal leuko-
cyte DNA or DNA from a known unmethylated cell line)
controls, and multiple water blanks. Serial dilutions (60 ng,
6 ng, 0.6 ng, 0.06 ng, and 0.006 ng) of Bisulfite-converted
Universal Methylated Human DNA Standard were used to
construct a standard curve for each gene.
2.9. Statistical Analysis for qMSP andMethylation Array Data.
qMSP values were adjusted for DNA input by expressing
results as ratios between 2 absolute measurements. The rela-
tive level ofmethylatedDNA for each gene in each samplewas
determined as a ratio of qMSP for the amplified gene toACTB
and then multiplied by 100 for easier tabulation ((average
DNA quantity of methylated gene of interest/average DNA
quantity for internal reference gene b-actin) × 100) [19].
The samples were categorized as unmethylated or methylated
based on detection of methylation above a threshold set for
each gene. For quality control, all amplification curves were
visualized and scored without knowledge of the clinical data.
ROC curves were used to identify a cut-off ratio above the
highest control ratio observed for each gene to set specificity
at 100% [10]. Hypermethylation ratios for each gene were
compared between cancer HCC and non-HCC samples.
Once the best individually discriminating genes were found,
2-gene and 3-gene panels were tested to identify the highest
sensitivity with specificity set at 100% for each gene.
3. Results
Patient characteristics are summarized in Table 1 (note that,
for some samples analyzed by qMSP, clinical information
was missing and only patients’ histology was known). The
majority (58%) of the patients in our study were men. The
mean age of the patients was 47.3 years, andmost (56%) of the
patients were over 50 years old.The ethnicities of the patients
in our study wereWhite (74%), Black (23%), and Asian (2%).
The most frequent HCC risk factor seen in the patients of
this study was viral infection with HCV (35%) or HBV (5%).
Interestingly, cryptogenic cirrhosis was seen in 26% of the
patients. Alcohol intake was the risk factor for a handful of
patients (5%). “M” represents that a sample has a value above
the qMSPmethylation threshold for that gene.This sample is
methylated. “U” represent that a sample has a value below the
qMSPmethylation threshold for that gene.This sample is not
methylated
3.1. Global and Gene-Specific Differential DNA Promoter
Methylation Arrays. We used scatterplots to compare differ-
ential DNA methylation values between HCC and normal
liver tissue samples hybridized to the 385K Nimblegen tiling
array after DNA enrichment with MeDIP (MeDIP-chip).
Figure 1 shows representative scatterplots and histograms in
which a decrease in globalDNApromotermethylation clearly
distinguishes between HCC and normal tissue. Scatterplots
and histograms of genome-wide DNA methylation array
data provide a snapshot of the differences in methylation
patterns between tumor and normal samples. Genome-
wide hypomethylation was observed in the tumors when
compared to normal samples. A representative tumor sample
has less significant methylated probes (1,503) than either one
of the normal liver tissue samples (2,585 and 2,887, resp.).
Furthermore, the median methylation score was significantly
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Table 1: Hepatocellular carcinoma risk factors per participant.
ID Age Sex Race Type Etiology Histology Size AFP B4GALT1 RASSF1A SSBP2
16 53 M W Normal Cryptogenic Cirrhosis ⋅ ⋅ U U U
22 58 M W Normal HCV Cirrhosis ⋅ ⋅ U U U
30 65 M W Normal HCV Cirrhosis ⋅ ⋅ U U U
31 67 M W Normal HCV Cirrhosis ⋅ ⋅ U M M
21 58 M W Normal Other Cirrhosis ⋅ ⋅ U U U
15 50 F B Normal Cryptogenic Noncirrhotic ⋅ ⋅ U U U
2 19 F B Normal HCV Noncirrhotic ⋅ ⋅ U U M
29 62 F W Normal HCV Noncirrhotic ⋅ ⋅ U U U
9 40 F B Normal Other Noncirrhotic ⋅ ⋅ U U U
4 26 F W Normal Other Noncirrhotic ⋅ ⋅ U U M
13 45 F W Normal Other Noncirrhotic ⋅ ⋅ U U U
35 81 F W Normal Other Noncirrhotic ⋅ ⋅ U M U
18 54 M B Normal Cryptogenic Noncirrhotic ⋅ ⋅ U U U
10 42 M W Normal Other Noncirrhotic ⋅ ⋅ U M U
20 55 M W Normal Other Noncirrhotic ⋅ ⋅ U M M
36 unk unk unk Normal unk unk ⋅ ⋅ U U M
37 unk unk unk Normal unk unk ⋅ ⋅ U U U
38 unk unk unk Normal unk unk ⋅ ⋅ U U M
39 53 M M Normal ETOH Noncirrhotic ⋅ ⋅ U U U
40 19 F F Normal HCV Noncirrhotic ⋅ ⋅ U U U
41 57 M M Normal HCV Cirrhosis ⋅ ⋅ U U U
42 60 M M Normal HCV Cirrhosis ⋅ ⋅ U U U
5 28 F W Tumor Other HCC 2.5 1 M U U
28 62 F W Tumor HCV HCC 2.8 17 U M M
17 53 M W Tumor Cryptogenic HCC 4 10 U M U
7 40 F B Tumor Other HCC 3.7 1 U U M
25 59 F AS Tumor HBV HCC 4 20 M M M
3 20 F W Tumor HCV HCC 4 unk M U U
27 60 M B Tumor HCV/ETOH HCC 4 20 M M M
11 45 M W Tumor HCV HCC 5.0 unk M M M
8 40 M W Tumor HCV HCC 5.5 11110 U U U
32 67 M W Tumor HCV HCC 6 2 M M M
33 73 M W Tumor Other HCC 6 2 U M M
6 37 M B Tumor Other HCC 7.0 54071 U M U
23 58 M W Tumor Other HCC 7.2 4659 M U M
14 50 F B Tumor Cryptogenic HCC 9 1594 U M U
26 60 M W Tumor Cryptogenic HCC 12 146 M M M
19 55 M W Tumor Other HCC 17 5 U M M
12 45 F B Tumor HVB/HCV HCC unk unk U U U
24 58 M W Tumor HCV HCC unk unk M M M
1 19 F B Tumor HCV HCC 25 19764 U M M
34 74 F W Tumor Cryptogenic HCC 4.5 unk M M U
43 42 M M Tumor Other HCC 15 NA M M U
44 26 F M Tumor Other HCC 8 NA M M U
45 12 F M Tumor Other HCC NA NA M M U
46 NA NA NA Tumor NA HCC NA NA U M U
47 NA NA NA Tumor NA HCC NA NA U M M
48 NA NA NA Tumor NA HCC NA NA U U M
49 45 F F Tumor Cryptogenic HCC 1.5 NA M M M
M: Methylated; U: Unmethylated; unk: unknown.
















































































































Figure 1: Scatterplots and histograms for a representative set of one tumor sample and two normal samples hybridized to oligonucleotide
methylation tiling arrays. The methylation score is on the 𝑌-axis of the scatterplots and the number of methylated probes is on the 𝑋-axis.
The number of methylated probes is on the 𝑌-axis of the histograms and the methylation score is on the𝑋-axis.
lower for the tumor sample (5.7) than for the normal samples
(6.7).
We used unsupervised clustering of the Illumina Bead-
Chip array results to create a heat map based on correlation,
which clearly separates the three HCC samples from the
adjacent normal liver sample (Figure 2). Please note that, for
one normal sample, even though it clustered with the other
two adjacent normal samples, probe-specific methylation
levels were higher than expected.
3.2. Promoter Hypermethylation in Tumor and Adjacent
Normal Samples. Our search of publicly available methyla-
tion databases found a combined total of 549 methylated
genes when searching for hepatocellular carcinoma (389)
and hepatoma (160), 451 of which were unique genes. After
crossing that list with the list of frequently methylated
genes we identified using methylation arrays, we chose three
genes for validation, one gene that was already found to
be hypermethylated in HCC by several groups (RASSF1A)
and two genes that we have reported as methylated in
other tumors but not in HCC (B4GALT1 and SSBP2). We
quantified the promoter methylation of these 3 genes in 27
HCC samples and 22 adjacent normal samples. To determine
the frequency of methylation, we used primers and probes
for qMSP previously designed in our laboratory based on
bisulfite sequencing data [20, 21].
RASSF1Awas methylated in 14/27 (52%) of HCC samples
and in 1/17 (6%) of adjacent normal samples. B4GALT1 was
methylated in 14/27 (52%) of HCC samples and in 0/20 (0%)
of adjacent normal samples. SSBP2 was methylated in 14/27
(52%) of HCC samples and in 6/18 (33%) of adjacent normal
samples. Most of the HCC samples (78%) had at least one
of these three genes methylated, while less than half of the
adjacent normal samples (44%) had one gene methylated.
Methylation of at least two of these genes was observed in
70% of the HCC samples and in 0% of the adjacent normal
samples (Figures 3(a)-3(b)).
ROC curves were used to determine the sensitivity and
specificity of the three genes individually and combined in
a biomarker panel (Figure 4). RASSF1A methylation in the
examined tissue samples had a sensitivity of 52%, a specificity
of 100%, and an AUC of 0.73 (95% CI, 0.57–0.88). B4GALT1
methylation exhibited a sensitivity of 52%, a specificity of
100%, and an AUC of 0.75 (95% CI, 0.71–0.89). For SSBP2,
the sensitivity was 38%, specificity was 100%, and the AUC
was 0.58 (95% CI, 0.40–0.75) (Table 2).
6 Gastroenterology Research and Practice
Y
1
1 5 17 27578
−0.222
NNN TTT
Figure 2: Heat map of the promoter-wide methylation data
obtained by hybridizing to the Infinium array three hepatocellular
carcinoma (HCC) samples and three nontumor liver samples from
patients with no known liver disease. A dendrogram (tree graph) of
the average beta values for three HCC samples and three nontumor
samples was created with Spotfire (Somerville, MA). Unsupervised
hierarchical clustering was performed with the unweighted average
method using correlation as the similarity measure and ordering by
average values. The color red was selected to represent high scores
and the color green to represent low scores.
Table 2: Specificity, sensitivity, and area under the curve results
for RASSF1A, B4GALT1, and SSBP2 in HCC, individually, and in
a combined panel of the three genes.
RASSF1A B4GALT1 SSBP2 Combinedpanel of 3 genes
Specificity 100% 100% 100% 100%
Sensitivity 52% 52% 38% 68%
AUC 0.73 0.75 0.58 0.82
When the methylation status of these three genes was
included in a logistic regression model together with gender,
age, and etiology, the sensitivity was 87%, the specificity
100%, and the AUC was 0.91 (Figure 4(b)). No statistically
significant associationwas observed between patient’s clinical
data and methylation.
4. Discussion
HCC is the most common primary malignancy of the liver
in adults, the fifth most common solid tumor, and the third
most common cause of cancer death worldwide [22]. HCC
incidence and death rates are steadily rising in the United
States, and HCC displays the highest average annual percent
increase in incidence among the top 15 cancers [23]. HCC
patients and people at risk of developing HCC have profound
unmet medical and public health needs. Advances in HCC
treatment, such as liver transplantation, surgical resection,
and loco regional therapies, have only impacted a fraction
of the population at risk. More than 70% of HCC patients
present with advanced disease and will not benefit from these
treatment modalities or from the sole chemotherapeutic
agent approved for advanced HCC patients [24].
Epigenetic lesions in DNA without mutations in the
coding regions have been shown to be common phenomena
in the pathogenesis of a wide range of cancers, especially the
methylation-mediated silencing of tumor suppressor genes
such as VHL, p16INK4a, E-cadherin, hMLH1, BRCA1, and
LKB1 [25, 26]. Moreover, promoter hypermethylation has
been linked with a large number of genes involved in HCC
including RASSF1A, APC, GSTP1, SOX 17, and RIZ1 [27–29].
Analysis of tissue specimens has revealed that DNAmethyla-
tion alterations, the best-understood epigenomic biomarker,
play a part in a multistage carcinogenetic procedure leading
to HCC [27].
Differential methylation has been identified from the
early precancerous stages, in association with inflammation
and/or persistent infectionwithHBVorHCV seen in chronic
hepatitis or liver cirrhosis to HCC lesions [30]. In addition,
concordance of hypermethylation patterns has been shown
in matching tissue and plasma DNA fromHCC patients [31].
Furthermore, aberrant methylation of a panel of three genes
has been reported in serum DNA, 1 to 9 years before clinical
diagnosis of HCC [32]. Therefore, unraveling epigenetic
alterations in HCC opened up possibilities for discovering
new biomarkers for detection and prognosis [9].
By using a study principle that combines promoter-wide
and gene-specific methylation platforms that interrogate the
promoter region, we were able to distinguish HCC from
non-HCC tissue. Our group and others have previously
shown that analytical platforms, which quantified global
DNA methylation in repetitive regions of the genome, could
also distinguish between HCC and non-HCC tissue [33, 34].
DNA methylation alterations in either the promoter or the
repetitive elements regions of the genomemay therefore serve
as useful molecular biomarkers for screening and clinical
management for HCC.
The primary goal of our study was to test whether a
small sample size is sufficient to provide information on
methylation-related studies by using Illumina BeadChip
assays and theNimblegen oligonucleotide arrays. Our discov-
ery set, although including a limited number of samples, was
able to identify genes differentially methylated in HCC when
compared to normal samples. Among them, there were genes
previously reported as also genes with a known role in HCC
and other cancer types. To further validate our findings and
the power of a genome-wide analysis based on a small sample
size, we generated a list of hypermethylated genes in HCC.
We ranked the list based on both the frequency in which the
genes had been identified in different studies and also in the
methylation arrays we used.
RASSF1A, SSBP2, and B4GALT1 were selected for further
study. Promoter hypermethylation of RASSF1A, SSBP2, and
B4GALT1 quantified by qMSP had a sensitivity ranging from
38% to 52%, a specificity of 100%, and an AUC from 0.58 to
0.75. A panel combining these genes with HCC risk factors
had a sensitivity of 87%, a specificity of 100%, and an AUC of
0.91.
As our knowledge of the HCC epigenome increases,
new therapeutic and clinical management strategies may be



























































Figure 3: Quantitative MSP results of hepatocellular carcinoma samples and adjacent normal liver samples that were bisulfite treated to
examine the promoter methylation status of RASSF1A, B4GALT1, and SSBP2. Scatter plots of quantitative MSP analysis of candidate gene
promoters. Twenty-two adjacent normal liver tissue samples and 27 hepatocellular carcinoma samples were tested for methylation for each of
the three genes by quantitative MSP.The relative level of methylated DNA for each gene in each sample was determined as a ratio of MSP for
the amplified gene to ACTB and then multiplied by 100 for easier tabulation (average value of duplicates of gene of interest/average value of
duplicates of ACTB × 100).The samples were categorized as unmethylated ormethylated based on detection of methylation above a threshold



























Figure 4: ROC curves for a panel of the three genes RASSF1A, B4GALT1, and SSBP2, individually, (a) and after adjusting a logistic regression
model with HCC risk factors: age, gender, ethnicity, and etiology. (b).
developed and new serum-based screening or needle biopsy-
based diagnostic tools may become available for subgroups
at risk for HCC. The pace of DNA methylation translational
research is expected to increase exponentially due to the rapid
advancement of high-throughput promoter-wide technolo-
gies, such as microarray and next-generation sequencing,
as well as the advent of user-friendly commercial kits for
methylation enrichment [35]. Restoring epigenetically altered
pathways is a current research endeavor that will probably
lead to the development of new therapeutic tools with
translational advantages in malignancies. We are advancing
into a new era of individualized molecular medicine, which
will allow successful bidirectional interactions between the
laboratory bench and patient therapies, based on a better
understanding of the genetic and epigenetic mechanisms of
human cancers, including HCC.
The aim of this paper was not to provide robust con-
clusions about specific biomarkers but rather to demon-
strate that discrimination between HCC and non-HCC liver
tissue using currently available technologies that quantify
promoter-wide and gene-specific DNA methylation alter-
ations is feasible. The usefulness of the markers showcased
in this paper still needs to be determined in follow-up
studies. However, the technological platforms we have used
in this project can have an immediate impact on clinical and
biomarker development studies.
5. Conclusion
Promoter-wide microarray technologies may be used to
identify methylation patterns that distinguish between HCC
and non-HCC tissue. These technologies are well suited
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for personalized diagnostics and clinical management. As
utilization costs of microarrays decrease, population-based
studies may also consider using custom-made microarrays
to examine large numbers of participants in prevention and
early detection studies. Furthermore, we have also shown
how qMSP analyses can be used for fast, accurate, and cost-
effective high-throughput validation of methylation frequen-
cies in a large number of samples. There is a potential to
test the arising genes’ lists to detect biomarkers for early
HCC detection in bodily fluids such as plasma, serum, or
urine and provide a noninvasive method to clinicians to
stratify patients of higher risk for HCC. As the field of
translational epigenomics moves forward, clinical tests using
these technologies will be warranted to determine their
usefulness and reliability in novel screening and clinical
management approaches for HCC.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This research was supported in part by the following Grant
Awards: NCI U01CA084986 and K01CA164092. The authors
want to thank Regina Santella for providing normal liver and
hepatocellular carcinoma samples and Rafael Irizarry for his
help and supervision in bioinformatics and biostatistics.
References
[1] N. Wong, W.-C. Lam, P. B.-S. Lai, E. Pang, W.-Y. Lau, and P. J.
Johnson, “Hypomethylation of chromosome 1 heterochromatin
DNA correlates with q-arm copy gain in human hepatocellular
carcinoma,” American Journal of Pathology, vol. 159, no. 2, pp.
465–471, 2001.
[2] Y. Saito, Y. Kanai, M. Sakamoto, H. Saito, H. Ishii, and S. Hiro-
hashi, “Overexpression of a splice variant of DNAmethyltrans-
ferase 3b, DNMT3b4, associated with DNA hypomethylation
on pericentromeric satellite regions during human hepatocar-
cinogenesis,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 99, no. 15, pp. 10060–10065,
2002.
[3] T. Moribe, N. Iizuka, T. Miura et al., “Methylation of multiple
genes as molecular markers for diagnosis of a small, well-
differentiated hepatocellular carcinoma,” International Journal
of Cancer, vol. 125, no. 2, pp. 388–397, 2009.
[4] S. H. Shin, B.-H. Kim, J.-J. Jang, K. S. Suh, and G. H. Kang,
“Identification of novel methylation markers in hepatocellular
carcinoma using amethylation array,” Journal of KoreanMedical
Science, vol. 25, no. 8, pp. 1152–1159, 2010.
[5] S. H. Tang, D. H. Yang, W. Huang, H. K. Zhou, X. H. Lu, and G.
Ye, “Hypomethylated P4 promoter induces expression of the
insulin-like growth factor-II gene in hepatocellular carcinoma
in a Chinese population,” Clinical Cancer Research, vol. 12, no.
14, pp. 4171–4177, 2006.
[6] B. Cho, H. Lee, S.W. Jeong et al., “Promoter hypomethylation of
a novel cancer/testis antigen gene CAGE is correlated with its
aberrant expression and is seen in premalignant stage of gastric
carcinoma,” Biochemical and Biophysical Research Communica-
tions, vol. 307, no. 1, pp. 52–63, 2003.
[7] W. Gao, Y. Kondo, L. Shen et al., “Variable DNA methylation
patterns associatedwith progression of disease in hepatocellular
carcinomas,” Carcinogenesis, vol. 29, no. 10, pp. 1901–1910, 2008.
[8] Y.-B. Deng, G. Nagae, Y. Midorikawa et al., “Identification of
genes preferentially methylated in hepatitis C virus-related
hepatocellular carcinoma,” Cancer Science, vol. 101, no. 6, pp.
1501–1510, 2010.
[9] H. Hernandez-Vargas, M.-P. Lambert, F. Le Calvez-Kelm et al.,
“Hepatocellular carcinoma displays distinct DNA methylation
signatures with potential as clinical predictors,” PloS ONE, vol.
5, no. 3, Article ID e9749, 2010.
[10] D. F. Calvisi, S. Ladu, A. Gorden et al., “Ubiquitous activation
of Ras and Jak/Stat pathways in humanHCC,”Gastroenterology,
vol. 130, no. 4, pp. 1117–1128, 2006.
[11] E. L. Sceusi, D. S. Loose, and C. J. Wray, “Clinical implications
of DNAmethylation in hepatocellular carcinoma,”HPB, vol. 13,
no. 6, pp. 369–376, 2011.
[12] J. Shen, S. Wang, Y. J. Zhang et al., “Exploring genome-wide
DNA methylation profiles altered in hepatocellular carcinoma
using Infinium HumanMethylation 450 BeadChips,” Epigenet-
ics, vol. 8, no. 1, pp. 34–43, 2013.
[13] M. O. Hoque, C.-C. R. Lee, P. Cairns, M. Schoenberg, and D.
Sidransky, “Genome-wide genetic characterization of bladder
cancer: a comparison of high-density single-nucleotide poly-
morphism arrays and PCR-based microsatellite analysis,” Can-
cer Research, vol. 63, no. 9, pp. 2216–2222, 2003.
[14] M. O. Hoque, O. Topaloglu, S. Begum et al., “Quantitative
methylation-specific polymerase chain reaction gene patterns
in urine sediment distinguish prostate cancer patients from
control subjects,” Journal of Clinical Oncology, vol. 23, no. 27,
pp. 6569–6575, 2005.
[15] P. C. Scacheri, G. E. Crawford, and S. Davis, “Statistics for ChIP-
chip and DNase hypersensitivity experiments on NimbleGen
arrays,”Methods in Enzymology, vol. 411, pp. 270–282, 2006.
[16] Y.-C. Fang, H.-C. Huang, and H.-F. Juan, “MeInfoText: asso-
ciated gene methylation and cancer information from text
mining,” BMC Bioinformatics, vol. 9, p. 22, 2008.
[17] X. He, S. Chang, J. Zhang et al., “MethyCancer: the database of
human DNA methylation and cancer,” Nucleic Acids Research,
vol. 36, no. 1, pp. D836–D841, 2008.
[18] Y. Huang, X. Chang, J. Lee et al., “Cigarette smoke induces pro-
moter methylation of single-stranded DNA-binding protein 2
in human esophageal squamous cell carcinoma,” International
Journal of Cancer, vol. 128, no. 10, pp. 2261–2273, 2011.
[19] G. B. A.Wisman, E. R. Nijhuis, M. O. Hoque et al., “Assessment
of gene promoter hypermethylation for detection of cervical
neoplasia,” International Journal of Cancer, vol. 119, no. 8, pp.
1908–1914, 2006.
[20] M. Brait, L. Maldonado, M. G. Noordhuis et al., “Association of
promoter methylation of VGF and PGP9. 5 with ovarian cancer
progression,” PLoS ONE, vol. 8, no. 9, Article ID e70878, 2013.
[21] M. Brait, M. Loyo, E. Rosenbaum et al., “Correlation between
BRAF mutation and promoter methylation of TIMP3, RAR-
beta2 and RASSF1A in thyroid cancer,” Epigenetics, vol. 7, no.
7, pp. 710–719, 2012.
[22] F. X. Bosch, J. Ribes, M. Dı́az, and R. Cléries, “Primary liver
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